Enabling  ||| S:0 E:9 ||| VBG
brain  ||| S:9 E:15 ||| NN
plasticity  ||| S:15 E:26 ||| NNS
and  ||| S:26 E:30 ||| CC
neurological  ||| S:30 E:43 ||| JJ
recovery  ||| S:43 E:52 ||| NN
in  ||| S:52 E:55 ||| IN
the  ||| S:55 E:59 ||| DT
ischemic  ||| S:59 E:68 ||| JJ
brain ||| S:68 E:73 ||| NN
:  ||| S:73 E:75 ||| :
effect  ||| S:75 E:82 ||| NN
of  ||| S:82 E:85 ||| IN
age  ||| S:85 E:89 ||| NN
and  ||| S:89 E:93 ||| CC
vascular  ||| S:93 E:102 ||| JJ
risk  ||| S:102 E:107 ||| NN
factors  ||| S:107 E:115 ||| NNS
as  ||| S:115 E:118 ||| IN
confounders  ||| S:118 E:130 ||| JJ
Cerebral  ||| S:130 E:139 ||| JJ
plasticity  ||| S:139 E:150 ||| NN
and  ||| S:150 E:154 ||| CC
neurological  ||| S:154 E:167 ||| JJ
recovery  ||| S:167 E:176 ||| NN
can  ||| S:176 E:180 ||| MD
be  ||| S:180 E:183 ||| VB
stimulated  ||| S:183 E:194 ||| VBN
in  ||| S:194 E:197 ||| IN
the  ||| S:197 E:201 ||| DT
ischemic  ||| S:201 E:210 ||| JJ
brain  ||| S:210 E:216 ||| NN
by  ||| S:216 E:219 ||| IN
exogenous  ||| S:219 E:229 ||| JJ
pharmacological  ||| S:229 E:245 ||| NN
and  ||| S:245 E:249 ||| CC
cell-based  ||| S:249 E:260 ||| JJ
treatments ||| S:260 E:270 ||| NNS
.  ||| S:270 E:272 ||| .
Neurons ||| S:272 E:279 ||| NNP
,  ||| S:279 E:281 ||| ,
neuroblasts  ||| S:281 E:293 ||| NN
and  ||| S:293 E:297 ||| CC
endothelial  ||| S:297 E:309 ||| JJ
cells  ||| S:309 E:315 ||| NNS
synergistically  ||| S:315 E:331 ||| VBP
interact  ||| S:331 E:340 ||| VBN
with  ||| S:340 E:345 ||| IN
each  ||| S:345 E:350 ||| DT
other  ||| S:350 E:356 ||| JJ
as  ||| S:356 E:359 ||| IN
a  ||| S:359 E:361 ||| DT
regenerative  ||| S:361 E:374 ||| JJ
triad ||| S:374 E:379 ||| NN
,  ||| S:379 E:381 ||| ,
creating  ||| S:381 E:390 ||| VBG
an  ||| S:390 E:393 ||| DT
environment  ||| S:393 E:405 ||| NN
in  ||| S:405 E:408 ||| IN
which  ||| S:408 E:414 ||| WDT
neurological  ||| S:414 E:427 ||| JJ
recovery  ||| S:427 E:436 ||| NN
takes  ||| S:436 E:442 ||| VBZ
place ||| S:442 E:447 ||| NN
.  ||| S:447 E:449 ||| .
Developmental  ||| S:449 E:463 ||| JJ
genetic  ||| S:463 E:471 ||| JJ
programs  ||| S:471 E:480 ||| NNS
are  ||| S:480 E:484 ||| VBP
reactivated ||| S:484 E:495 ||| VBN
.  ||| S:495 E:497 ||| .
Brain  ||| S:497 E:503 ||| NN
neurons  ||| S:503 E:511 ||| NNS
and  ||| S:511 E:515 ||| CC
capillary  ||| S:515 E:525 ||| JJ
cells  ||| S:525 E:531 ||| NNS
are  ||| S:531 E:535 ||| VBP
enabled  ||| S:535 E:543 ||| VBN
to  ||| S:543 E:546 ||| TO
sprout ||| S:546 E:552 ||| VB
,  ||| S:552 E:554 ||| ,
and  ||| S:554 E:558 ||| CC
glial  ||| S:558 E:564 ||| JJ
cells  ||| S:564 E:570 ||| NNS
support  ||| S:570 E:578 ||| VBP
plasticity  ||| S:578 E:589 ||| JJ
processes ||| S:589 E:598 ||| NNS
.  ||| S:598 E:600 ||| .
Until  ||| S:600 E:606 ||| IN
now ||| S:606 E:609 ||| RB
,  ||| S:609 E:611 ||| ,
the  ||| S:611 E:615 ||| DT
large  ||| S:615 E:621 ||| JJ
majority  ||| S:621 E:630 ||| NN
of  ||| S:630 E:633 ||| IN
studies  ||| S:633 E:641 ||| NNS
were  ||| S:641 E:646 ||| VBD
performed  ||| S:646 E:656 ||| VBN
in  ||| S:656 E:659 ||| IN
young ||| S:659 E:664 ||| JJ
,  ||| S:664 E:666 ||| ,
otherwise  ||| S:666 E:676 ||| RB
healthy  ||| S:676 E:684 ||| JJ
animals ||| S:684 E:691 ||| NNS
,  ||| S:691 E:693 ||| ,
which  ||| S:693 E:699 ||| WDT
lack  ||| S:699 E:704 ||| VBP
the  ||| S:704 E:708 ||| DT
risk  ||| S:708 E:713 ||| NN
factors  ||| S:713 E:721 ||| NNS
and  ||| S:721 E:725 ||| CC
co-morbidities  ||| S:725 E:740 ||| JJ
associated  ||| S:740 E:751 ||| VBN
with  ||| S:751 E:756 ||| IN
human  ||| S:756 E:762 ||| JJ
stroke ||| S:762 E:768 ||| NN
.  ||| S:768 E:770 ||| .
Recent  ||| S:770 E:777 ||| JJ
behavioral ||| S:777 E:787 ||| NN
,  ||| S:787 E:789 ||| ,
histochemical  ||| S:789 E:803 ||| NN
and  ||| S:803 E:807 ||| CC
molecular  ||| S:807 E:817 ||| JJ
biological  ||| S:817 E:828 ||| JJ
studies  ||| S:828 E:836 ||| NNS
have  ||| S:836 E:841 ||| VBP
shown  ||| S:841 E:847 ||| VBN
that  ||| S:847 E:852 ||| IN
restorative  ||| S:852 E:864 ||| JJ
brain  ||| S:864 E:870 ||| NN
responses  ||| S:870 E:880 ||| NNS
may  ||| S:880 E:884 ||| MD
differ  ||| S:884 E:891 ||| VB
between  ||| S:891 E:899 ||| IN
young  ||| S:899 E:905 ||| JJ
and  ||| S:905 E:909 ||| CC
old  ||| S:909 E:913 ||| JJ
animals ||| S:913 E:920 ||| NNS
,  ||| S:920 E:922 ||| ,
and  ||| S:922 E:926 ||| CC
that  ||| S:926 E:931 ||| IN
they  ||| S:931 E:936 ||| PRP
are  ||| S:936 E:940 ||| VBP
also  ||| S:940 E:945 ||| RB
modulated  ||| S:945 E:955 ||| VBN
by  ||| S:955 E:958 ||| IN
vascular  ||| S:958 E:967 ||| JJ
risk  ||| S:967 E:972 ||| NN
factors ||| S:972 E:979 ||| NNS
,  ||| S:979 E:981 ||| ,
such  ||| S:981 E:986 ||| JJ
as  ||| S:986 E:989 ||| IN
hyperlipidemia  ||| S:989 E:1004 ||| NN
and  ||| S:1004 E:1008 ||| CC
diabetes ||| S:1008 E:1016 ||| NN
,  ||| S:1016 E:1018 ||| ,
which  ||| S:1018 E:1024 ||| WDT
are  ||| S:1024 E:1028 ||| VBP
highly  ||| S:1028 E:1035 ||| RB
prevalent  ||| S:1035 E:1045 ||| JJ
in  ||| S:1045 E:1048 ||| IN
ischemic  ||| S:1048 E:1057 ||| JJ
stroke ||| S:1057 E:1063 ||| NN
.  ||| S:1063 E:1065 ||| .
We  ||| S:1065 E:1068 ||| PRP
claim  ||| S:1068 E:1074 ||| VBP
that  ||| S:1074 E:1079 ||| DT
age  ||| S:1079 E:1083 ||| NN
aspects ||| S:1083 E:1090 ||| NNS
,  ||| S:1090 E:1092 ||| ,
vascular  ||| S:1092 E:1101 ||| JJ
risk  ||| S:1101 E:1106 ||| NN
factors  ||| S:1106 E:1114 ||| NNS
and  ||| S:1114 E:1118 ||| CC
co-morbidities  ||| S:1118 E:1133 ||| NNP
should  ||| S:1133 E:1140 ||| MD
more  ||| S:1140 E:1145 ||| RBR
intensively  ||| S:1145 E:1157 ||| RB
be  ||| S:1157 E:1160 ||| VB
examined  ||| S:1160 E:1169 ||| VBN
in  ||| S:1169 E:1172 ||| IN
future  ||| S:1172 E:1179 ||| JJ
experimental  ||| S:1179 E:1192 ||| JJ
studies ||| S:1192 E:1199 ||| NNS
.  ||| S:1199 E:1201 ||| .
Confounding  ||| S:1201 E:1213 ||| JJ
effects  ||| S:1213 E:1221 ||| NNS
of  ||| S:1221 E:1224 ||| IN
age ||| S:1224 E:1227 ||| NN
,  ||| S:1227 E:1229 ||| ,
risk  ||| S:1229 E:1234 ||| NN
factors  ||| S:1234 E:1242 ||| NNS
and  ||| S:1242 E:1246 ||| CC
co-morbidities  ||| S:1246 E:1261 ||| NNP
should  ||| S:1261 E:1268 ||| MD
carefully  ||| S:1268 E:1278 ||| RB
be  ||| S:1278 E:1281 ||| VB
considered  ||| S:1281 E:1292 ||| VBN
in  ||| S:1292 E:1295 ||| IN
clinical  ||| S:1295 E:1304 ||| JJ
proof-of-concept  ||| S:1304 E:1321 ||| JJ
trials ||| S:1321 E:1327 ||| NNS
.  ||| S:1327 E:1329 ||| .
